Nuevolution discloses the identity of its “Cytokine X” program being Interleukin IL-17A
and initiates promotion of its small molecule IL-17A inhibitor program targeting inflammatory diseasesStockholm, 22 August 2018. Today, Nuevolution AB (publ) announced the identity of its “Cytokine X” program being a lead discovery program targeting inhibition of Interleukin IL-17A using small molecules. Nuevolution’s small molecules may offer access to both topical (e.g. cream based) treatment as well as safe tablet-based treatment, whereas currently marketed IL-17A inhibitors are injectable and high-cost antibodies that come with potential adverse reactions from the treatment. The company